Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,303 total articles
Exponent Inc. CEO Catherine Corrigan sold 3,920 shares on February 17, 2026, generating about $263,239, and on the same day exercised options for 5,606 shares valued at $151,095. The company reported fourth-quarter 2025 revenue of $147.4 million, an 8% year-over-year increase, and EPS of $0.49, above the $0.4738 estimate. After-hours trading slippe…
MapLight Therapeutics director Robert C. Malenka sold 12,116 shares of voting common stock on February 13, 2026, generating $220,632 in proceeds. The company, valued at roughly $753 million, has pushed forward timelines for two Phase 2 trials and received Fast Track designation for one of its lead candidates, while analysts hold a Strong Buy consen…
Peloton Interactive CEO Peter C. Stern sold 31,461 Class A shares on February 17, 2026, at a weighted average price of $4.1389 to cover tax liabilities tied to the settlement of Restricted Stock Units (RSUs). The sale generated about $130,213. Two days earlier he converted RSUs into 59,714 shares through option exercise. The moves come amid a nearl…
Dion C. Sanders, Peloton Interactive’s Chief Commercial Officer, sold 88,242 shares of Class A common stock on February 17, 2026, for roughly $365,039. Sanders had exercised 235,086 RSUs two days earlier. The insider activity coincides with Peloton’s fiscal 2026 second-quarter results, which came in below analyst estimates on both revenue and earni…
Michael R. McAlevey, HCA Healthcare's Executive Vice President and Chief Legal and Administrative Officer, completed a set of equity transactions in February 2026 that included an open-market sale, exercise and conversion of stock appreciation rights, and a subsequent disposition to satisfy tax obligations. These moves leave him with a reduced dire…
Voss Capital's Voss Value Master Fund reported a purchase of 25,000 Flywire (FLYW) shares on February 13, 2026, for roughly $274,795. The transaction increased the fund's direct stake to 2.3 million shares. The Voss group collectively holds more than 10% of Flywire. Separately, Deutsche Bank and Seaport Global issued positive guidance and price tar…
Sanford J. Hodes, Senior Vice President and Corporate Development Officer at Ryder System, sold 10,527 shares of the company's common stock on February 17, 2026, for $2,212,354 at $210.16 per share after exercising options to acquire 7,610 shares. The company also reported fourth-quarter 2025 earnings of $3.59 per share versus a $3.57 consensus, wh…
Laura H. Bethge, President of Celebrity Cruises at Royal Caribbean Cruises Ltd. (RCL), disposed of 7,854 shares on February 17, 2026, raising $2.56 million. The transaction leaves her with direct ownership of 32,786 shares and indirect ownership of 87 shares through a spouse. The move comes as Royal Caribbean reported Q4 2025 results that met analy…
BridgeBio Pharma Chief Accounting Officer Maricel Apuli reported two recent stock transactions in mid-February 2026, including a sale and a tax-withholding disposition. The company concurrently disclosed positive Phase 3 data for oral infigratinib in achondroplasia and completed a $550 million private offering of convertible senior notes due 2033. …
KKR director Matt Cohler purchased 43,872 shares of KKR & Co. Inc. on February 17, 2026, for a total of $4,514,428 at an average price of $102.90. The transaction increases his direct holdings to 45,477 shares, with an additional 97,568 shares held indirectly in trust. The purchase arrives after KKR reported Q4 2025 adjusted EPS below expectations …
Meta Platforms Chief Financial Officer Susan J. Li completed several equity transactions on February 15, 2026, including the sale of 6,418 Class A shares through a trust for $4,106,043 and the disposition of 11,160 shares withheld for RSU tax obligations valued at $7,139,833. Li also received 23,905 shares via RSU conversion and 13,935 shares via o…
BridgeBio Pharma director Scott Randal W. sold 10,000 shares of common stock on February 17, 2026, generating roughly $754,556 from multiple transactions priced between $74.3421 and $75.9261. The same day he exercised options to acquire 10,000 shares at $16.75 each for $167,500. After these moves he directly owns 11,589 shares and has an indirect h…
Vincent Retort, Executive Vice President for Module Business Unit R&D and Product Development at Lumentum Holdings Inc. (LITE), sold 2,736 shares of company stock on Feb. 17, 2026, for roughly $1.87 million under a previously adopted Rule 10b5-1 plan. The transactions occurred at prices between $530.8035 and $557.8428. The sales follow a Feb. 15 di…
Louisiana-Pacific Corp CEO William Bradley Southern sold 19,232 shares on February 17 and 18, 2026, under a pre-established Rule 10b5-1 plan. The transactions totaled $2,509,317 at prices from $86.87 to $90.12. The disclosure follows the company’s mixed fourth-quarter results, which beat EPS expectations but missed revenue forecasts and triggered a…
PG&E Corp's CEO Patricia K. Poppe sold 31,250 shares on February 18, 2026, for a total of $559,375 under a pre-arranged Rule 10b5-1(c) trading plan. The transaction leaves Poppe with 216,921 shares directly and 1,863,960 shares indirectly through a revocable trust. The disclosure comes as PG&E reported fourth-quarter 2025 earnings per share of $0.3…
Howard F. Hambleton, president of FirstCash Holdings, sold 4,000 shares on February 18, 2026, at $185.12 per share, generating proceeds of $740,480. The transaction was carried out under a 10b5-1 trading plan established on September 11, 2025. After the sale, Hambleton directly holds 35,406 shares. Separately, Canaccord Genuity reiterated its Buy r…
Protagonist Therapeutics director Lewis T. Williams sold 18,000 shares on February 17, 2026, in transactions totaling $1.48 million and exercised options to acquire an equal number of shares at $10.84 each. The activity was disclosed in a Form 4 filing with the Securities and Exchange Commission. Multiple analysts have recently revised price target…
Arvinas Inc.'s chief medical officer, Noah Berkowitz, had 5,685 shares of common stock sold on February 13, 2026, at $11.89 per share to satisfy tax withholding related to vested restricted stock units. The automatic sale generated $67,594 in proceeds and followed a company filing that specifies the transaction was not a discretionary trade. The co…
Electronic Arts Chairman and CEO Andrew Wilson sold 5,000 shares of company stock on February 17, 2026, generating $997,484 in proceeds. The disposals were executed under a 10b5-1 plan and come as EA shares trade close to their 52-week high. The company recently reported robust bookings growth and rising adjusted operating income, while analysts va…
Electronic Arts Chief People Officer Vijayanthimala Singh sold 1,200 shares on February 17, 2026, netting $240,756 under a pre-arranged 10b5-1 plan. The transaction comes while EA trades close to its 52-week high and ahead of a pending merger where a key regulatory waiting period has expired. The company reports solid bookings and adjusted operatin…
International Seaways President and CEO Lois K. Zabrocky sold 2,000 shares of company stock on February 17, 2026, under a Rule 10b5-1 plan, generating proceeds of $127,919. The company also disclosed the sale or agreements to sell five older vessels for about $185 million net. Market commentary from BTIG shows increased price targets for peers amid…
PubMatic's Chief Accounting Officer, Lisa Gimbel, sold 1,277 shares of Class A common stock on February 17, 2026, for about $8,027 while concurrently receiving equity through restricted stock units. The company has also recruited senior commercial executives to expand its AI-driven advertising capabilities in North America. Citizens reiterated a Ma…
Rivian CEO Robert J. Scaringe sold 34,900 shares of Class A common stock on February 18, 2026, for about $586,236 under a Rule 10b5-1 plan. An earlier tax-related disposition of 35,578 shares on February 15, 2026, was valued at $630,797. Despite the sales, InvestingPro data indicates Rivian's balance sheet has more cash than debt and that the compa…
Neuronetics President and CEO Keith J. Sullivan sold 33,847 shares on February 12, 2026, in a transaction disclosed on a Form 4 filing with the SEC. The sale, intended to satisfy tax obligations tied to vested restricted stock units, totaled $55,847. Separately, preliminary unaudited results show the company posted an 86% increase in fourth-quarter…
Day One Biopharmaceuticals reported an insider sale by Chief Commercial Officer Lauren Merendino on February 17, 2026, totaling 5,814 shares for about $67,447. Two days earlier she exercised 15,162 restricted stock units. The company disclosed preliminary 2025 net product revenue for OJEMDA of $155.4 million, issued 2026 U.S. net product revenue gu…
